Capital International, Inc./CA/ - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 238 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2021. The put-call ratio across all filers is 1.29 and the average weighting 0.1%.

Quarter-by-quarter ownership
Capital International, Inc./CA/ ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2022$1,094,000
-47.0%
26,429
-23.6%
0.02%
-17.2%
Q2 2022$2,065,000
-31.5%
34,613
-16.6%
0.03%
-14.7%
Q1 2022$3,013,000
-64.1%
41,492
-58.4%
0.03%
-56.4%
Q4 2021$8,384,000
-73.6%
99,698
-71.6%
0.08%
-74.5%
Q3 2021$31,702,000
-16.7%
351,499
-11.9%
0.31%
-9.7%
Q2 2021$38,062,000
-21.2%
399,181
-5.8%
0.34%
-24.5%
Q1 2021$48,272,000
-28.2%
423,957
-12.7%
0.45%
-28.0%
Q4 2020$67,258,000
+70.2%
485,866
+1.0%
0.62%
+43.4%
Q3 2020$39,520,000
+5.7%
480,833
+0.6%
0.44%
-4.6%
Q2 2020$37,378,000
+86.7%
477,858
+6.1%
0.46%
+35.3%
Q1 2020$20,015,000
+5.9%
450,495
+1.8%
0.34%
+28.1%
Q4 2019$18,906,000
-6.2%
442,660
-6.0%
0.26%
-13.2%
Q3 2019$20,152,000
+324.4%
471,065
+530.1%
0.30%
-8.7%
Q2 2019$4,748,000
+42.5%
74,765
+55.6%
0.33%
-16.4%
Q1 2019$3,333,000
+74.4%
48,050
+9.4%
0.40%
+52.1%
Q4 2018$1,911,000
-44.2%
43,941
-2.0%
0.26%
-41.6%
Q3 2018$3,423,000
+30.8%
44,841
+31.7%
0.45%
+11.8%
Q2 2018$2,617,000
+24.7%
34,040
-17.3%
0.40%
+32.0%
Q1 2018$2,098,000
+4.6%
41,140
-4.9%
0.30%
+1.7%
Q4 2017$2,005,000
-18.3%
43,240
-6.2%
0.30%
-17.0%
Q3 2017$2,455,000
-25.0%
46,100
-12.5%
0.36%
-23.3%
Q2 2017$3,273,000
-15.3%
52,700
-7.5%
0.47%
-0.4%
Q1 2017$3,863,000
+16.6%
57,000
+21.0%
0.47%
+14.1%
Q4 2016$3,312,000
+32.6%
47,100
+33.8%
0.41%
+38.7%
Q3 2016$2,497,00035,2000.30%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q2 2021
NameSharesValueWeighting ↓
First Light Asset Management, LLC 441,159$39,788,0002.62%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 103,100$9,286,0002.24%
Rock Springs Capital Management LP 801,109$72,252,0001.52%
Avidity Partners Management LP 455,000$41,036,0000.91%
Motley Fool Asset Management LLC 134,357$12,118,0000.79%
FEDERATED HERMES, INC. 3,987,032$359,590,0000.68%
EMERALD ADVISERS, LLC 196,124$17,688,0000.64%
Ergoteles LLC 128,100$11,553,0000.42%
Tekla Capital Management LLC 140,726$12,692,0000.41%
Beck Bode, LLC 14,990$1,352,0000.38%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders